Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Schett, Georg; Chen, Warner; Gao, Sheng; Chakravarty, Soumya D.; Shawi, May; Lavie, Frederic; Zimmermann, Miriam; Sharaf, Mohamed; Coates, Laura C.; Siebert, Stefan

doi:10.1186/s13075-023-03125-4

Table 1 Correlation of baseline cytokine biomarker levels with baseline clinical activity measures in participants with TNFi-IR PsA in the COSMOS biomarker cohort

From: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

	Clinical activity in the COSMOS biomarker cohort
Biomarker		PsA duration	PsO BSA	PASI (0–72)	SJC (0–66)	TJC (0–68)	DAS28-CRP	PASDAS	DAPSA
CRP	Rho	0.12	0.09	0.08	-0.04	0.03	*0.39*	*0.26*	0.12
CRP	p value	0.128	0.274	0.325	0.640	0.743	< 0.0001	0.0014	0.1330
SAA	Rho	0.09	0.08	0.04	0.03	0.04	*0.32*	0.22	0.15
SAA	p value	0.266	0.349	0.620	0.721	0.634	0.0001	0.0075	0.0683
IL-6	Rho	0.24	-0.01	-0.02	0.06	0.12	*0.32*	0.24	0.18
IL-6	p value	0.004	0.944	0.834	0.499	0.149	0.0001	0.0029	0.0277
IL-17A	Rho	0.07	*0.48*	*0.49*	0.16	0.06	0.18	0.22	0.13
IL-17A	p value	0.399	< 0.0001	< 0.0001	0.045	0.446	0.029	0.0076	0.1202
IL-17F	Rho	0.21	*0.44*	*0.41*	0.14	0.0	0.10	0.14	0.10
IL-17F	p value	0.009	< 0.0001	< 0.0001	0.086	0.265	0.219	0.0850	0.2189
IL-22	Rho	0.12	0.21	*0.25*	–0.06	0.00	0.04	–0.19	0.24
IL-22	p value	0.131	0.0091	0.0024	0.4862	0.961	0.6532	0.0559	0.0147
IFNγ	Rho	0.1068	0.0214	0.0076	–0.0112	0.0034	0.0435	0.07	0.02
IFNγ	p value	0.1935	0.7949	0.9263	0.8916	0.9674	0.5968	0.3785	0.8391
IL-10	Rho	0.0776	0.0627	0.0718	0.0132	0.0141	–0.0356	0.04	0.01
IL-10	p value	0.3453	0.446	0.3824	0.8729	0.864	0.6651	0.6139	0.8901
IL-8	Rho	0.2004	0.1104	0.0578	–0.0268	0.0486	0.0846	0.16	0.05
IL-8	p value	0.0139	0.1787	0.4823	0.7448	0.5548	0.3031	0.0496	0.536
TNFα	Rho	0.213	0.0032	0.0371	–0.0445	–0.014	0.0416	0.07	0.01
TNFα	p value	0.0089	0.9688	0.6523	0.5888	0.8646	0.6125	0.4211	0.928
sICAM-1	Rho	0.0678	0.0067	0.0599	-0.0512	-0.0089	0.1282	0.08	0.02
sICAM-1	p value	0.4097	0.9349	0.4664	0.5342	0.9137	0.1179	0.354	0.7711
sVCAM-1	Rho	0.1155	–0.0325	–0.0414	0.0992	0.1499	0.101	0.13	0.16
sVCAM-1	p value	0.1594	0.6928	0.6148	0.2271	0.067	0.2186	0.1227	0.0568

Statistics based on Spearman linear regression
Bolded text highlights significant correlation between biomarker and clinical activity (Rho > 0.25; p < 0.05)
BSA, body surface area; CRP, C-reactive protein; DAPSA, Disease Activity index for Psoriatic Arthritis; DAS28-CRP, 28- Disease Activity Score with C-reactive protein; IL, interleukin; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule-1; SJC, swollen joint count; sVCAM, soluble vascular cell adhesion molecule; TJC, tender joint count; TNF, tumor necrosis factor; TNFi-IR, tumor necrosis factor inhibitor-inadequate response

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us